
Pestly Is a Better Essential Oil Bug Repellent (But We Still Don't Recommend It)
There is no question that Pestly represents a significant step forward for essential oil repellents. But does it go far enough to replace a picaridin- or DEET-based spray? We asked repellency researcher Laurence Zwiebel, a professor of biological science and pharmacology at Vanderbilt University, and he told us that, even with Pestly's advancements in mind, essential oil repellents 'to me, have not shown the level of robust, prolonged, durable repellency, full stop.'
Another significant difference holding this newcomer back: Although Pestly has shown decent repellency against mosquitoes, it makes no claims against ticks. Considering the prevalence of Lyme and other tick-borne diseases, we believe that this is a serious issue, and one we can't ignore. Both picaridin and DEET have proven repellency against those harmful little bugs.
'What I tell people is, if you want to go for a walk in the woods, you should bring some serious stuff,' Zwiebel told us when we asked him to share his general advice on using repellents. 'If you wanna just sit on your back deck, I would not put anything on and just stick a big-ass fan on the deck to blow at you, and you'll be more comfortable, and you won't have any insects bothering you.'
If you don't like the idea of spraying picaridin or DEET on your skin, he suggests spraying it just on your clothing. He also likes permethrin-treated clothing: 'A barrier is always a better thing than a chemical, and a barrier treated with a chemical is the best,' he explained.
When you talk to an expert like Zwiebel, or the many other researchers we've spoken to over our several years of reporting on this topic, you get the impression that taking any unnecessary risk, while knowing what is at stake, doesn't make sense. That's especially true considering that more effective repellents, like those containing picaridin and DEET, are so readily available.
So although we appreciate what Pestly is doing and admire its willingness to set a new standard for essential oil repellents, we stand by our recommendation to use a repellent with a 20% concentration of picaridin or a 25% concentration of DEET. It will provide all-day protection against mosquitoes and ticks.
But still, Pestly has provided a glimmer of hope for folks seeking an alternative, and it represents a solid step forward toward a repellent that we might someday recommend for general use.
This article was edited by Megan Beauchamp and Harry Sawyers. We don't recommend using any essential-oil bug repellents. There's no way to know what kind of protection you're getting (if any) or how long it will last.
Our repellent recommendations are EPA approved, backed by experts, and tested by us.
Bug zappers kill the wrong bugs—to control bugs without a spray repellent, use a spatial repellent or a fan instead.
These products create a bug-free barrier, and the best ones are long-lasting, effective, and easy to refill or recharge.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Medscape
9 minutes ago
- Medscape
Which Class of ER Degrader Is Better?
Vepdegestrant, an investigational estrogen receptor (ER) degrader, known as a proteolysis-targeting chimera (PROTAC ), outshone the commonly used selective estrogen receptor degrader (SERD) fulvestrant in a phase 3 trial of second-line treatment for a subset of patients with breast cancer. The VERITAC-2 trial included patients with ER-positive/human epidermal growth factor receptor 2-negative (ER+/HER2-), locally advanced or metastatic disease who had failed prior treatment with cyclin-dependent kinase 4/6 (CDK 4/6) inhibitors and endocrine therapy, and no exposure to chemotherapy in the advanced setting. Only a subset of the study cohort, those with estrogen receptor 1-mutant disease, experienced a statistically significant and clinically meaningful improvement in progression-free survival (PFS) when treated with vepdegestrant compared with patients treated with fulvestrant. 'These results support vepdegestrant as a potential monotherapy treatment option for patients with previously treated ESR1 -mutant ER+/HER2- advanced breast cancer,' said lead author Erika P. Hamilton, MD, a medical oncologist and director of Breast Cancer and Gynecologic Cancer Research at Sarah Cannon Research Institute, Nashville, Tennessee, during a press conference for the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. The findings were simultaneously published in the New England Journal of Medicine . Vepdegestrant is not approved by the US Food and Drug Administration, but received fast-track status in February 2024 as monotherapy for this patient population. It is the first and only PROTAC ER degrader to be evaluated in a phase 3 clinical trial in breast cancer. PROTACs represent a novel class of therapeutic agents that harness the proteasome to selectively degrade target proteins. 'There's no established consensus for patients getting treatment in the second-line setting after progression on endocrine therapy and a CDK 4/6 inhibitor,' explained Hamilton. 'One of the mainstays of our treatment really has been fulvestrant, which clearly has some challenges. First, it's administered intramuscularly, and second, in a post-CDK 4/6 landscape, we know that progression-free survival is very short — on the order of less than 2 months.' Besides fulvestrant, the oral SERD elacestrant was FDA-approved in January 2023, and other oral SERDs are in development, she noted. Trial Design The new trial included 624 patients with advanced ER+/HER2- disease that had progressed following one or two lines of endocrine therapy and a CDK 4/6 inhibitor. 'They could not have received fulvestrant already or chemotherapy, and patients had to have benefited from their previous line of endocrine therapy for at least 6 months to enter the study,' Hamilton noted. Study participants were also stratified by the presence or absence of visceral disease, as well as the presence of an ESR1 mutation (n = 270). Such mutations are a common cause of acquired resistance found in approximately 40% of patients in the second-line setting, according to a press release from the drug developer. Patients were randomly assigned 1:1 to 28-day treatment cycles of either 200 mg oral vepdegestrant once daily, or 500 mg intramuscular fulvestrant on day 1 and day 15 of the first cycle, and then on day 1 of each subsequent cycle. The primary endpoint was PFS by blinded, independent central review, first in patients with ESR1 mutations and then in the entire cohort. Key secondary endpoints were overall survival, objective response rate, and clinical benefit rate, which was defined as the rate of confirmed clinical or partial response at any time, or stable disease, nonclinical response, or nonprogressive disease for at least 24 weeks. Vepdegestrant vs Fulvestrant The study met its key primary endpoint, showing a median PFS of 5.0 months with vepdegestrant compared with 2.1 months with fulvestrant (hazard ratio [HR] 0.57; P < .001) in the 270 patients with ESR1 mutations. At 6 months, twice as many patients in the vepdegestrant arm remained progression-free compared with those in the fulvestrant arm (45.2% vs 22.7%). However, this primary endpoint was not significantly different between groups when calculated for the entire patient population (HR, 0.83; P = .07). For the key secondary endpoints, among patients with ESR1 mutations, the clinical benefit rate was more than double in patients receiving vepdegestrant (42.1% vs 20.2%). Similarly, the objective response rate was more than four times higher (18.6% vs 4%) Commenting in a press release, ASCO breast cancer expert Jane Lowe Meisel, MD, said that although the trial found that vepdegestrant worked better than fulvestrant in patients with ESR1 mutations, 'on average, patients did not have prolonged responses on either agent, highlighting the need for combination therapies and continued development in this space.' Meisel is co-director of Breast Medical Oncology at the Winship Cancer Institute of Emory University School of Medicine in Atlanta, Georgia. 'Overall survival was very immature at the time of this analysis, with only 20% of the anticipated events occurring,' added lead investigator Hamilton. Treatment-emergent adverse events (TEAEs) led to discontinuation in 3% of patients taking vepdegestrant and 1% of patients taking fulvestrant. TEAEs leading to dose reductions occurred in 2% of the vepdegestrant group and none in the fulvestrant group. The three most common AEs of any grade were fatigue (27% in vepdegestrant group, 16% fulvestrant group) and increased aspartate aminotransferase and alanine aminotransferase levels of any grade (14% vepdegestrant group, 10% fulvestrant group). Oral SERDS vs Vepdegestrant Side Effects Compared to oral SERDs, vepdegestrant has a favorable side effect profile, Hamilton said. 'Oral SERDs have prominent GI side effects as their most frequent side effect.' But, across all grades, rates of both vomiting and diarrhea were only 6% with vepdegestrant. GI side effects tend to be more common, 'in the 30% or 40% range with oral SERDs,' she told Medscape Medical News . Study discussant William John Gradishar, MD, emphasized the importance of reducing side effects. ' Vepdegestrant now joins a growing list of drugs that perform better than current standard of care monotherapy' in the ESR1 -mutant population, he noted in the session. But the reality is that most of these drugs are being developed to be used in combination with targeted therapies, 'and increased toxicity can be expected with doublet therapy…Quality of life measures as experienced and reported by patients are critical, and even modest changes in symptom and functional domains should not be minimized,' said Gradishar, professor of breast oncology at Northwestern University Feinberg School of Medicine, Chicago, Illinois. 'Vepdegestrant has demonstrated compelling preclinical activity and encouraging early clinical data supporting its efficacy in degrading ER,' said Albert Grinshpun, MD, in an interview with Medscape Medical News . Grinshpun, head of the Breast Cancer Service at Shaare Zedek Medical Center and The Hebrew University, Jerusalem, Israel, said his initial takeaway from the study is that 'vepdegestrant now stands alongside other oral SERDs, such as elacestrant and imlunestrant, in demonstrating superiority over fulvestrant, specifically in the context of ESR1 -mutant [disease].' 'Importantly, the treatment landscape for patients progressing on CDK 4/6 inhibitors is rapidly evolving, with a growing shift toward combination therapies rather than fulvestrant monotherapy,' he said. 'In my view, vepdegestrant has established itself as a promising endocrine backbone for future combination strategies. Its favorable toxicity profile makes it particularly well-suited for pairing with a range of targeted agents or even antibody-drug conjugates, including inhibitors of PIK3CA and KAT6 , in the pursuit of more effective therapeutic regimens.' The study was jointly funded by Arvinas Estrogen Receptor, Inc. and Pfizer. Hamilton disclosed consulting or advisory roles with Accutar Biotechnology (Inst), Arvinas (Inst), AstraZeneca (Inst), Circle Pharma (Inst), Daiichi Sankyo (Inst), Ellipses Pharma (Inst), Entos (Inst), Fosun Pharma (Inst), Genentech/Roche (Inst), Gilead Sciences (Inst), Janssen (Inst), Jazz Pharmaceuticals (Inst), Jefferies (Inst), Johnson & Johnson (Inst), Lilly (Inst), Medical Pharma Services (Inst), Mersana (Inst), Novartis (Inst), Olema Pharmaceuticals (Inst), Pfizer (Inst), Stemline Therapeutics (Inst), Tempus (Inst), Theratechnologies (Inst), Tubulis GmbH (Inst), Verascity Science (Inst), and Zentalis (Inst). Hamilton has also received research funding from AbbVie (Inst), Accutar Biotech (Inst), Acerta Pharma (Inst), ADC Therapeutics (Inst), Akeso Biopharma (Inst), Amgen (Inst), Aravive (Inst), ArQule (Inst), Artios (Inst), Arvinas (Inst), AstraZeneca (Inst), AtlasMedx (Inst), BeiGene (Inst), Black Diamond Therapeutics (Inst), Bliss Biopharmaceutical (Inst), Boehringer Ingelheim (Inst), Bristol-Myers Squibb (Inst), Cascadian Therapeutics (Inst), Clovis Oncology (Inst), Compugen (Inst), Context Therapeutics (Inst), Cullinan Oncology (Inst), Curis (Inst), CytomX Therapeutics (Inst), Daiichi Sankyo (Inst), Dana-Farber Cancer Institute (Inst), Dantari (Inst), Deciphera (Inst), Duality Biologics (Inst), eFFECTOR Therapeutics (Inst), Eisai (Inst), Ellipses Pharma (Inst), Elucida Oncology (Inst), EMD Serono (Inst), Fochon Pharmaceuticals (Inst), Fujifilm (Inst), G1 Therapeutics (Inst), Genentech/Roche (Inst), Gilead Sciences (Inst), H3 Biomedicine (Inst), Harpoon (Inst), Hutchison MediPharma (Inst), Immunogen (Inst), Immunomedics (Inst), Incyte (Inst), Infinity Pharmaceuticals (Inst), Inspirna (Inst), InventisBio (Inst), Jacobio (Inst), K-Group Beta (Inst), Karyopharm Therapeutics (Inst), Kind Pharmaceuticals (Inst), Leap Therapeutics (Inst), Lilly (Inst), Loxo (Inst), Lycera (Inst), MabSpace Biosciences (Inst), Macrogenics (Inst), MedImmune (Inst), Mersana (Inst), Merus (Inst), Millennium (Inst), Molecular Templates (Inst), Myriad Genetics (Inst), Novartis (Inst), Nucana (Inst), Olema Pharmaceuticals (Inst), OncoMed (Inst), Oncothyreon (Inst), ORIC Pharmaceuticals (Inst), Orinove (Inst), Orum Therapeutics (Inst), Pfizer (Inst), PharmaMar (Inst), Pieris Pharmaceuticals (Inst), Pionyr (Inst), Plexxikon (Inst), Prelude Therapeutics (Inst), ProfoundBio (Inst), Radius Health (Inst), Regeneron (Inst), Relay Therapeutics (Inst), Repertoire Immune Medicines (Inst), Rgenix (Inst), Seagen (Inst), Sermonix Pharmaceuticals (Inst), Shattuck Labs (Inst), Silverback Therapeutics (Inst), Stem CentRx (Inst), Stemline Therapeutics (Inst), Sutro Biopharma (Inst), Syndax (Inst), Syros Pharmaceuticals (Inst), Taiho Pharmaceutical (Inst), TapImmune Inc. (Inst), Tesaro (Inst), Tolmar (Inst), Torque (Inst), Treadwell Therapeutics (Inst), Verastem (Inst), Zenith Epigenetics (Inst), and Zymeworks (Inst). Meisel disclosed consulting or advisory roles with AstraZeneca, GE Healthcare, Genentech, Novartis, Olema Oncology, Pfizer, SeaGen, Sermonix Pharmaceuticals, and Stemline, and research funding from AstraZeneca (Inst), Olema Oncology (Inst), Pfizer (Inst), Seagen (Inst), and Sermonix Pharmaceuticals (Inst). Grinshpun disclosed honoraria from GSK, Lilly, Novartis, and AstraZeneca, and travel from Roche, Pfizer, and AstraZeneca. Gradishar disclosed consulting or advisory roles with AstraZeneca , Genentech/Roche, Gilead Sciences, Merck, Novartis, Pfizer.


Car and Driver
24 minutes ago
- Car and Driver
1971 Ford F-100 Pickup Is Today's Pick on Bring a Trailer
The fifth-generation F-series ran from the 1967 to 1972 model years. This was from the era when the F-series was a real working pickup, long before it became America's favorite means of personal transport. This truck is nicely presented, looking just as it did back in the day. By the end of the 1970s, the Ford F-Series was the best-selling truck in America. A couple of years later, it was the best-selling vehicle, a title it has retained for more than four decades. But lets wind the clock back to the beginning of the 1970s, when the F-Series was just a truck, but a charming one. Bring a Trailer This 1971 F-100 Sport Custom is up for sale on Bring a Trailer (which, like Car and Driver, is part of Hearst Autos). It's so square-jawed handsome it could take over the lead role on Yellowstone now that Kevin Costner has bowed out. It's a time capsule in a cowboy hat, what with it's Boxwood Green over Seafoam Green two-tone paint and its steel wheels with hub caps. (Extra points to the seller for resisting the urge to go the restomod route with a lift kit and oversized wheels and tires.) This good ol' Ford was sold new in Oregon City in (you guessed it) Oregon. Situated just south of Portland, Oregon City marks the end of the Oregon Trail, and is filled with folks whose ancestors successfully dodged dysentery and took up forestry and farming. Bring a Trailer A '71 F-100 would have been a lot nicer ride down the Oregon Trail than a Conestoga wagon (lack of gas stations notwithstanding) but it's a pretty basic truck by modern standards. The Sport Custom was a mid-tier grade, with a rubber floor covering and a simple bench seat. This example's luxuries are limited to a three-speed automatic transmission, power steering, power brakes, and an aftermarket cassette player. You're gonna want to get some Conway Twitty tapes for that. Bring a Trailer Under the hood is a 360-cubic-inch V-8, and much recent mechanical servicing has been done, including replacing the water pump, the fuel pump, drive belts, the battery, and some gaskets. Elsewhere in the truck, the shocks have been replaced, and the braking system gone through with new parts. It should drive as honest as it looks. At 54 years old, this F-100 has earned a quiet retirement, but there is a spray-in bedliner, so it could earn its keep around the house hauling mulch or supplies for weekend DIY projects. The auction ends on June 6. Brendan McAleer Contributing Editor Brendan McAleer is a freelance writer and photographer based in North Vancouver, B.C., Canada. He grew up splitting his knuckles on British automobiles, came of age in the golden era of Japanese sport-compact performance, and began writing about cars and people in 2008. His particular interest is the intersection between humanity and machinery, whether it is the racing career of Walter Cronkite or Japanese animator Hayao Miyazaki's half-century obsession with the Citroën 2CV. He has taught both of his young daughters how to shift a manual transmission and is grateful for the excuse they provide to be perpetually buying Hot Wheels. Read full bio


Forbes
37 minutes ago
- Forbes
Derrick Lewis Says He Nearly Had To Beg To Get UFC Nashville Fight
ST LOUIS, MISSOURI - MAY 11: (L-R) Derrick Lewis battles Rodrigo Nascimento of Brazil in a ... More heavyweight fight during the UFC Fight Night event at Enterprise Center on May 11, 2024 in St Louis, Missouri. (Photo by Josh Hedges/Zuffa LLC via Getty Images) Derrick Lewis, who holds the record for most knockout wins in UFC history, has his next fight booked. However, the former UFC heavyweight title challenger, who has not set foot inside the Octagon for more than a year, said securing the UFC Nashville main event fight opposite Tallison Teixeira was not easy. "It's crazy that nobody's fighting right now," Lewis recently told MMA Junkie. "Heavyweight, I don't know what's going on. I damn near had to beg to get this fight, so I don't know what's going on. Hopefully we can stay active after this." UFC Nashville takes place on July 12 at Bridgestone Arena in Nashville, Tennessee. Lewis (28-12-0-1) is the No. 9 fighter in the official UFC heavyweight rankings. The 40-year-old former UFC title challenger is coming off a May 2024 knockout win over Rodrigo Nascimento. Lewis, who owns the record for most knockouts in UFC history with 15, is 2-4 in his past six trips to the Octagon dating back to February 2022. Lewis has been with the UFC since 2014. He also has the UFC record for most finishes in the heavyweight division with 15. No active UFC heavyweight has as many fights in the Octagon as Lewis does at 29. Lewis has a UFC heavyweight record eight fight-night bonus awards. Lewis was scheduled to face Jhonata Diniz in November, but he was forced to withdraw from that contest after he had weighed in because of an undisclosed medical issue. Teixeira (8-0) joined the UFC in 2024 with a knockout win on a Dana White Contender Series card. The 25-year-old made his official UFC debut in February 2025, scoring a first-round knockout and a "Performance of the Night" bonus in a win over Justin Tafa. The UFC is wasting no time in throwing Teixeira into the deep end of the heavyweight pool, giving him a veteran opponent in a main event contest. All eight of Teixeira's career wins have come via first-round stoppage (seven knockouts, one submission). He has been a pro since 2021. He is ranked No. 14 in the UFC's heavyweight weight class. Lewis said of Teixeira, "I know he's Brazilian, and he's a tall guy. He's a heavyweight, so pretty sure he's got knockout power. I didn't watch any of his fights yet, nothing like that, but my coach told me he's got a lot of first-round knockouts. ... I've been training for like four months now, non-stop really, down to every day, and I never did that before. I'm coming into this fight, I'm pretty sure I'm going to be in great shape. My six pack will be back." "Yeah, I'm comfortable," Lewis added. "I like fighting tall guys. It aligns with my right hand. The way I throw my right hand, it aligns with it." We will have more information on Derrick Lewis vs. Tallison Teixeira and the UFC Nashville fight card as information becomes available. The UFC Fight Night card is airs on ESPN and ESPN+.